TipRanks
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
AVBP
ArriVent BioPharma, Inc.
RESEARCH TOOLSreports
Want to see AVBP full AI Analyst Report?

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

92 Followers
See the Price Targets and Ratings of:

AVBP Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
ArriVent
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$44.57
▲(43.13% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $44.57 with a high forecast of $50.00 and a low forecast of $40.00. The average price target represents a 43.13% change from the last price of $31.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","34":"$34","51":"$51","25.5":"$25.5","42.5":"$42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.57142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25.5,34,42.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.54,31.113846153846154,32.68769230769231,34.261538461538464,35.83538461538461,37.40923076923077,38.98307692307692,40.55692307692308,42.13076923076923,43.70461538461538,45.27846153846154,46.85230769230769,48.426153846153845,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.54,30.696263736263735,31.85252747252747,33.00879120879121,34.16505494505495,35.32131868131868,36.47758241758242,37.63384615384615,38.79010989010989,39.94637362637363,41.10263736263736,42.2589010989011,43.41516483516483,{"y":44.57142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.54,30.344615384615384,31.14923076923077,31.953846153846154,32.75846153846154,33.56307692307692,34.36769230769231,35.17230769230769,35.97692307692308,36.78153846153846,37.58615384615385,38.39076923076923,39.19538461538461,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.82,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.54,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$44.57Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45
Buy
44.51%
Upside
Reiterated
09/15/26
ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Guggenheim
Truist Financial Analyst forecast on AVBP
Supawat Thongthip
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (NASDAQ: AGMB), Nuvation Bio (NYSE: NUVB) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$43
Buy
38.09%
Upside
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$40
Buy
28.45%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Cellectis SA (NASDAQ: CLLS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$47
Buy
50.93%
Upside
Reiterated
08/17/26
Robert Burns Raises ArriVent Price Target to $47, Maintains Buy on Firmonertinib Late‑Stage Upside
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
60.57%
Upside
Reiterated
08/13/26
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$45
Buy
44.51%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Alterity Therapeutics (NASDAQ: ATHE)
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42
Buy
34.87%
Upside
Reiterated
08/12/26
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45
Buy
44.51%
Upside
Reiterated
05/29/26
B. Riley Securities Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
$32→$47
Buy
50.93%
Upside
Reiterated
11/11/25
ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45
Buy
44.51%
Upside
Reiterated
09/15/26
ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Guggenheim
Truist Financial Analyst forecast on AVBP
Supawat Thongthip
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (NASDAQ: AGMB), Nuvation Bio (NYSE: NUVB) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$43
Buy
38.09%
Upside
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$40
Buy
28.45%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Cellectis SA (NASDAQ: CLLS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$47
Buy
50.93%
Upside
Reiterated
08/17/26
Robert Burns Raises ArriVent Price Target to $47, Maintains Buy on Firmonertinib Late‑Stage Upside
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
60.57%
Upside
Reiterated
08/13/26
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$45
Buy
44.51%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Alterity Therapeutics (NASDAQ: ATHE)
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42
Buy
34.87%
Upside
Reiterated
08/12/26
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45
Buy
44.51%
Upside
Reiterated
05/29/26
B. Riley Securities Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
$32→$47
Buy
50.93%
Upside
Reiterated
11/11/25
ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OMCLOmnicell
KNSAKiniksa Pharmaceuticals
ACHVAchieve Life Sciences
AHCOAdaptHealth
ZVRAZevra Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

3 Months
Yigal NochomovitzCiti
Success Rate
10/14 ratings generated profit
71%
Average Return
+3.03%
Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +3.03% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
10/13 ratings generated profit
77%
Average Return
+27.59%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +27.59% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
17/17 ratings generated profit
100%
Average Return
+36.11%
Copying Robert Burns's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
6
5
6
6
Buy
12
14
12
10
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
20
17
16
12
In the current month, AVBP has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 44.57.
Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$1.05 with a range of -$1.16 to -$0.84. The previous quarter’s EPS was -$1.05. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s earnings estimate for AVBP is -$1.05 with a range of -$1.16 to -$0.84. The previous quarter’s EPS was -$1.05. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 44.57.
    What is AVBP’s upside potential, based on the analysts’ average price target?
    ArriVent BioPharma, Inc. has 43.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVBP a Buy, Sell or Hold?
          ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is ArriVent BioPharma, Inc.’s price target?
            The average price target for ArriVent BioPharma, Inc. is 44.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $40.00. The average price target represents 43.13% Increase from the current price of $31.14.
              What do analysts say about ArriVent BioPharma, Inc.?
              ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of AVBP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.